EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

Alessia Cavalleri, Besjana Xhahysa, Silvia Mutti, Rosalba Monica Ferraro, Elena Laura Mazzoldi, Mirko Farina, Alessandro Leoni, Luca Garuffo, Federica Trenta, Federica Re, Vera Radici, Eugenia Accorsi Buttini und 7 weitere

Cell Biology International · 2025-05 · 49 (5) · 570-586

DOI: 10.1002/cbin.70007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Biology International, 2025-03. Verfasst von Alessia Cavalleri und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Sciences, University of Brescia, Unit of Blood Diseases and Bone Marrow Transplant, ASST Spedali Civili, Bres…. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic Myeloid Leukemia (CML) is characterized by the BCR::ABL1 fusion gene, driving uncontrolled myeloid cell proliferation. Furthermore, metabolic dysregulation contributes to disease progression. Despite the efficacy of tyrosine kinase inhibitors (TKIs), unresolved clinical needs persist, necessitating refined preclinical models. This study compared responses of three commonly used CML cell lines (K562, LAMA84, KCL22) to five TKIs (imatinib, nilotinib, dasatinib, bosutinib, ponatinib) and a Specifically Targeting the ABL Myristoyl Pocket (STAMP) inhibitor commonly used in clinical settings. Using morphological assessments, viability and metabolic activity assays, glutamate intake evaluations, and gene expression analyses we observed distinct responses among cell lines. TKIs and STAMP inhibitor treatments showed varying impacts on morphological features, cell viability, metabolic activity, and gene expression profiles, highlighting significant differences in cellular responses. This emphasizes the necessity of considering cellular heterogeneity in CML research. This comprehensive comparison provides valuable insights for refining preclinical models and enhancing translational relevance in CML research and treatment development. Understanding the diverse responses of CML cell lines to TKIs and STAMP inhibitor facilitates the selection of appropriate models for specific research questions, ultimately improving the accuracy and reliability of preclinical studies in CML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsHumansCell Line, TumorCell SurvivalCell ProliferationPyridazinesDasatinibImatinib MesylateQuinolinesFusion Proteins, bcr-ablK562 CellsPyrimidinesAntineoplastic AgentsNitrilesAniline CompoundsImidazoles

Stichwörter der Autor:innen

K562KCL22LAMA84STAMP inhibitorchronic myeloid leukemia (CML)digital PCRtyrosine kinase inhibitors (TKIs)

Substanzen

Protein Kinase InhibitorsPyridazinesDasatinibImatinib MesylateQuinolinesFusion Proteins, bcr-ablnilotinibPyrimidinesAntineoplastic AgentsNitriles

Autor:innen und Institutionen

  • Department of Clinical and Experimental Sciences, University of Brescia, Unit of Blood Diseases and Bone Marrow Transplant, ASST Spedali Civili, Brescia, Italy.
  • Centro di Ricerca Emato-Oncologica AIL (CREA), ASST Spedali Civili, Brescia, Italy.
  • Department of Molecular and Translational Medicine, University of Brescia, "Angelo Nocivelli" Institute for molecular medicine, ASST Spedali Civili, Brescia, Italy.
  • Hematology, ASST Spedali Civili, Brescia, Italy.
  • National Center for Gene Therapy and Drug based on RNA Technology-CN3, Padova, Italy.

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Cavalleri, A., Xhahysa, B., Mutti, S., Ferraro, R. M., Mazzoldi, E. L., Farina, M., Leoni, A., Garuffo, L., Trenta, F., Re, F., Radici, V., Buttini, E. A., Morello, E., Magliano, G., Cancelli, V., Giliani, S. C., Malagola, M., Russo, D., & Bernardi, S. (2025). Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent. Cell Biology International, 49(5), 570-586. https://doi.org/10.1002/cbin.70007

Vancouver

Cavalleri A, Xhahysa B, Mutti S, Ferraro RM, Mazzoldi EL, Farina M, et al. Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent. Cell Biology International. 2025;49(5):570-586. doi:10.1002/cbin.70007

BibTeX
@article{Cavalleri2025,
  author = {Cavalleri, Alessia and Xhahysa, Besjana and Mutti, Silvia and Ferraro, Rosalba Monica and Mazzoldi, Elena Laura and Farina, Mirko and Leoni, Alessandro and Garuffo, Luca and Trenta, Federica and Re, Federica and Radici, Vera and Buttini, Eugenia Accorsi and Morello, Enrico and Magliano, Gabriele and Cancelli, Valeria and Giliani, Silvia Clara and Malagola, Michele and Russo, Domenico and Bernardi, Simona},
  title = {Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent},
  journal = {Cell Biology International},
  year = {2025},
  volume = {49},
  number = {5},
  pages = {570--586},
  doi = {10.1002/cbin.70007}
}
Kostenlos starten →